Adagio Medical to Showcase ULTA Technology at Heart Rhythm 2026 — Adagio Medical Holdings, Inc.

Event summary

Adagio Medical's ULTA technology for ventricular tachycardia treatment will be featured in multiple presentations at the Heart Rhythm 2026 conference from April 23-26.
The FULCRUM-VT trial results, a pivotal study for FDA approval, will be presented as a late-breaking clinical trial on April 26.
ULTA technology is currently CE Marked and under evaluation in the U.S. via the FULCRUM-VT trial with 209 patients enrolled.
Presentations will include real-world patient series insights, procedural outcomes, and case-based reviews from leading cardiac specialists.

The big picture

Adagio Medical is positioning its ULTA technology as a potential game-changer in catheter ablation for ventricular tachycardia, a market with significant unmet needs. The Heart Rhythm 2026 conference presentations represent a critical opportunity to demonstrate clinical efficacy and safety data ahead of a potential FDA approval decision. Success in this space could position Adagio as a key player in the growing cardiac arrhythmia treatment market, which is driven by an aging population and increasing prevalence of structural heart disease.

What we're watching

Regulatory Pathway: Whether the FULCRUM-VT trial results will support a successful FDA premarket approval application for Adagio's vCLAS Cryoablation System.
Commercial Expansion: The pace at which Adagio can expand its ULTA technology beyond Europe into other global markets pending U.S. approval.
Clinical Adoption: How real-world patient data and specialist presentations at Heart Rhythm 2026 will influence physician adoption of ULTA technology.